Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 23, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis

PHILADELPHIA, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and other...
September 17, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study

PHILADELPHIA, Sept. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the approval by the Board of Directors for a Patient...
September 15, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Disease Symptoms

PHILADELPHIA, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today the publication in the current issue of the peer reviewed Journal of Clinical and Cellular...
January 12, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum

PHILADELPHIA, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has conducted new in vitro studies of natural killer...
June 03, 2014 13:06 ET | Source: AIM ImmunoTech Inc.

Hemispherx Announces That the University of Texas Medical Branch Confirms Activity of Alferon(R) N Against MERS (Middle East Respiratory Syndrome) Virus

PHILADELPHIA, June 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has confirmed that one of its advanced stage biological products, Alferon® N, inhibits...
May 27, 2014 09:26 ET | Source: AIM ImmunoTech Inc.

Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen(R) Formulations

PHILADELPHIA, May 27, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that on May 13, 2014, the United States Patent Office issued U.S....
May 21, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets

PHILADELPHIA, May 21, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced the preliminary stage agreement required to manufacture...
March 19, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference

PHILADELPHIA, March 19, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) will participate in the 11th Biennial International Research and Clinical Conference to be held in San...
March 10, 2014 11:00 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS) in Three Additional Latin America Countries

PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it and its partner in Latin America, GP Pharm, are planning...
November 19, 2013 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Sponsors Chronic Fatigue Syndrome Conference at Mount Sinai Medical Center in New York

PHILADELPHIA, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its sponsorship of the Conference on "Diagnosis, Treatments and New Developments in ME and CFS" ("Myalgic...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right